Stasior To Lead Build-Out of Data Infrastructure for the Genetic Diagnostic and Therapeutic Technology Company
MENLO PARK, CA - May 23, 2019 - Avellino Labs, global biotechnology and genetic science innovators, announced today the addition of William F. Stasior to the companys Executive Advisory Committee and consultant to the company. Stasior will advance Avellino Labs genetic data management infrastructure to support the companys growth and expanding application of its technology in health and precision medicine.
Bill brings tremendous knowledge and skill in developing platforms for managing complex data systems and we are extremely pleased to work with him as we build out our robust genetic services profile, said Avellino Labs Chairman of the Board Gene Lee. Ultimately, we hope to derive industry and life-changing findings through the analysis of genetic data via artificial intelligence engines and applications."
Stasior brings decades of experience at some of Silicon Valleys most recognizable technology companies to support Avellino Labs plans for growth in the genetic service provider sector. Most recently, Stasior led the team responsible for Siri, Apples intelligent personal assistant. As a member of Amazons senior executive team, Stasior led search and navigation at the companys A9 subsidiary. Previous stints include Altavista, Netcentives and Oracle. His background includes research positions at the Massachusetts Institute of Technology (MIT) and the Charles Stark Draper Laboratory while earning his undergrad and doctorate degrees in Electrical Engineering and Computer Science from MIT.
Since its establishment, Avellino Labs has tested over 720,000 patients, primarily in Korea and Japan, for various forms of genetic eye diseases known collectively as corneal dystrophies. Now, the company is preparing for a global roll-out of its latest diagnostic innovation, in addition to the ongoing development of its novel gene-editing therapeutic products, both of which have applications beyond ophthalmology.
Delivering on the potential of genetic data to address a broad array of health issues is an exciting opportunity, said Stasior. Avellino Labs has built a foundation for genetic diagnosis and therapeutics in ophthalmology and, with a strong data platform, we can rapidly expand the companys capabilities into other areas of disease research and healthcare.
Stasior joins the members of Avellino Labs Executive Advisory Committee supporting the companys strategic expansion plans with best practices from a wide array of data-based business sectors:
- Sanford R. (Sandy) Climan, President and CEO, Entertainment Media Ventures, Inc., CEO And Representative Director, All Nippon Entertainment Works, Inc.
- Robert (Bob) Sikorski, M.D., Ph.D., Managing Director, Woodside Way Ventures
- Jonathan (Jack) Lord, M.D., CEO of The Miller School and Uhealth-University of Miami Health System
- Jeffrey (Jeff) Finer, M.D., Ph.D., Chairman, Dexcom, Inc. and venture partner, Third Rock Ventures
About Avellino Labs
Avellino Labs is a global leader in gene therapy and molecular diagnostics and the pioneer in precision medicine for eye care. Avellino Labs is pioneering CRISPR gene editing to manage and potentially cure inherited diseases. Avellino Labs continues to expand its diagnostics capabilities, building on the success of the world's first DNA test to confirm the presence of genetic indicators that are positively associated with corneal dystrophies, providing life-changing information for patient treatment decisions and follow-up care. Avellino Labs is headquartered in Silicon Valley, California, with operations in Korea, Japan, China and the UK.
Avellino Labs was named a 2015 Technology Pioneer by the World Economic Forum based on its potential to impact global health.
To learn more, please visit http://www.avellino.com/us/ or follow us on Twitter @Avellinolab_USA.
###